PENTOXIFYLLINE DOES NOT PREVENT THE CYTOKINE-INDUCED FIRST DOSE REACTION FOLLOWING OKT3-A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY1,2
- 1 February 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 61 (4) , 573-577
- https://doi.org/10.1097/00007890-199602270-00010
Abstract
The use of OKT3 as an immunosuppressive agent is accompanied by increased cytokine production and constellation of side effects collectively termed cytokine release syndrome (CRS). Pentoxifylline (PTF) inhibits synthesis of some cytokines, and has been shown to attenuate CRS when administered before OKT3. In this double-blinded, placebo-controlled study, 46 renal allograft recipients were randomized to receive either PTF (800 mg q 8 hr for at least 24 h) p.o. or placebo, along with methylprednisolone (7 mg/kg), diphenhydramine, and acetaminophen, prior to beginning OKT3 as therapy for acute rejection. Patients were observed, and symptoms scored semiquantitatively. Despite the presence of therapeutic PTF levels(721±726 ng/ml), the frequency and severity of side effects (fever, chills, headache, neurocortical symptoms, dyspnea, nausea, vomiting, diarrhea) did not differ between treatment groups. Likewise PTF did not affect renal function or immunologic response to OKT3, with similar graft and patient survival in both groups. Plasma levels of TNF α, IFN γ, IL-6, and IL-8 increased as predicted following OKT3 administration, without significant differences between PTF and placebo groups. In this controlled, multicenter trial, pretreatment with oral PTF was ineffective in attenuating OKT3-related CRS in renal allograft recipients.Keywords
This publication has 18 references indexed in Scilit:
- THE EFFECTS OF ORAL PENTOXIFYLLINE ON THE CYTOKINE RELEASE SYNDROME DURING INDUCTIVE OKT3Transplantation, 1994
- EVIDENCE THAT ANTIHUMAN TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY PREVENTS OKT3-INDUCED ACUTE SYNDROMETransplantation, 1992
- USE OF INDOMETHACIN TO MINIMIZE THE ADVERSE REACTIONS ASSOCIATED WITH ORTHOCLONE OKT3 TREATMENT OF KIDNEY ALLOGRAFT REJECTIONTransplantation, 1992
- OKT3 first-dose reaction: Association with T cell subsets and cytokine releaseKidney International, 1991
- Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.The Journal of Experimental Medicine, 1990
- IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATIONTransplantation, 1990
- Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activationEuropean Journal of Immunology, 1990
- Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortalityLife Sciences, 1989
- Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofyllineBiochemical and Biophysical Research Communications, 1988
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985